Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies.
作者信息
Arashiro Takeshi, Arima Yuzo, Kuramochi Jin, Muraoka Hirokazu, Sato Akihiro, Chubachi Kumi, Oba Kunihiro, Yanai Atsushi, Arioka Hiroko, Uehara Yuki, Ihara Genei, Kato Yasuyuki, Yanagisawa Naoki, Nagura Yoshito, Yanai Hideki, Ueda Akihiro, Numata Akira, Kato Hideaki, Oka Hideaki, Nishida Yusuke, Ooki Takao, Nidaira Yuki, Stucky Ashley, Suzuki Tadaki, Smith Chris, Hibberd Martin, Ariyoshi Koya, Suzuki Motoi
机构信息
Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.
Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
出版信息
Euro Surveill. 2023 Jan;28(4). doi: 10.2807/1560-7917.ES.2023.28.4.2300034.
Abstract
摘要
相似文献
1
Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies.致编辑的信：在通过观察性研究评估新冠病毒疾病（COVID-19）疫苗效力时考虑高风险行为的重要性。
Euro Surveill. 2023 Jan;28(4). doi: 10.2807/1560-7917.ES.2023.28.4.2300034.
2
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).新型冠状病毒病 19（COVID-19）疫苗对日本德尔塔主导和奥密克戎主导期间有症状的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性：一项多中心前瞻性病例对照研究（与 SARS-CoV-2 感染相关的因素和 COVID-19 疫苗的有效性研究）。
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
3
Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.2021 年 3 月至 10 月估计的 COVID-19 疫苗对 SARS-CoV-2 感染后血清转换的有效性。
Vaccine. 2023 Apr 6;41(15):2596-2604. doi: 10.1016/j.vaccine.2023.03.006. Epub 2023 Mar 9.
4
COVID-19 vaccination status and testing rates in Finland-A potential cause for bias in observational vaccine effectiveness analysis.芬兰的 COVID-19 疫苗接种状况和检测率-观察性疫苗效力分析中存在偏倚的潜在原因。
Influenza Other Respir Viruses. 2022 Sep;16(5):842-845. doi: 10.1111/irv.12993. Epub 2022 Apr 27.
5
Letter to the editor: More data on vaccine efficacy/effectiveness of COVID-19 vaccines against asymptomatic SARS-CoV-2 infection.致编辑的信：关于新冠病毒疫苗对无症状SARS-CoV-2感染的效力/效果的更多数据
Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100826.
6
COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.基于西班牙严重急性呼吸道感染（SARI）哨点监测的 COVID-19 疫苗对因 SARS-CoV-2 住院的有效性：一项基于测试阴性设计的研究。
Influenza Other Respir Viruses. 2022 Nov;16(6):1014-1025. doi: 10.1111/irv.13026. Epub 2022 Jul 26.
7
Host factors and vaccine efficacy: Implications for COVID-19 vaccines.宿主因素与疫苗效力：对 COVID-19 疫苗的启示。
J Med Virol. 2022 Apr;94(4):1330-1335. doi: 10.1002/jmv.27485. Epub 2021 Dec 7.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings.系统评价评估 COVID-19 疫苗真实世界有效性的方法学研究：为资源有限环境提供建议。
PLoS One. 2022 Jan 11;17(1):e0261930. doi: 10.1371/journal.pone.0261930. eCollection 2022.
10
Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic.mRNA 疫苗对 SARS-CoV-2 的真实世界疫苗有效性：中等规模诊所的病例对照研究。
Hum Vaccin Immunother. 2022 Dec 30;18(7):2147353. doi: 10.1080/21645515.2022.2147353. Epub 2022 Dec 2.
引用本文的文献
1
Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics.在日本和菲律宾针对新冠疫情开展新冠疫苗有效性研究的经验：对未来疫情及潜在大流行的启示
Western Pac Surveill Response J. 2025 Jun 4;16(2):1-8. doi: 10.5365/wpsar.2025.16.2.1157. eCollection 2025 Apr-Jun.
2
Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study.在阴性对照研究中，公共卫生和社会措施的强度与SARS-CoV-2疫苗的有效性相关。
medRxiv. 2025 May 8:2025.05.08.25327221. doi: 10.1101/2025.05.08.25327221.
3
Sociobehavioural factors associated with SARS-CoV-2 infection and COVID-19 vaccine effectiveness against medically attended, symptomatic SARS-CoV-2 infection in the Philippines: a prospective case-control study (FASCINATE-P study).菲律宾与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染及新冠病毒疾病19（COVID-19）疫苗预防有医疗就诊记录的有症状SARS-CoV-2感染有效性相关的社会行为因素：一项前瞻性病例对照研究（FASCINATE-P研究）
Western Pac Surveill Response J. 2025 Jan 15;16(1):1-12. doi: 10.5365/wpsar.2025.16.1.1131. eCollection 2025 Jan-Mar.
4
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.含BA.1以及BA.4/BA.5的二价新冠mRNA疫苗在日本BA.5流行期预防有症状的SARS-CoV-2感染的有效性
Open Forum Infect Dis. 2023 May 3;10(6):ofad240. doi: 10.1093/ofid/ofad240. eCollection 2023 Jun.
本文引用的文献
1
COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.新冠病毒（COVID-19）疫苗在德尔塔（Delta）变异株流行期间针对 SARS-CoV-2 感染的有效性：一项全国性研究，对暴露机会进行了调整，荷兰，2021 年 7 月至 12 月。
Euro Surveill. 2022 Nov;27(45). doi: 10.2807/1560-7917.ES.2022.27.45.2200217.
2
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).新型冠状病毒病 19（COVID-19）疫苗对日本德尔塔主导和奥密克戎主导期间有症状的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性：一项多中心前瞻性病例对照研究（与 SARS-CoV-2 感染相关的因素和 COVID-19 疫苗的有效性研究）。
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
3
Behavioral factors associated with SARS-CoV-2 infection in Japan.与日本 SARS-CoV-2 感染相关的行为因素。
Influenza Other Respir Viruses. 2022 Sep;16(5):952-961. doi: 10.1111/irv.12992. Epub 2022 Apr 26.
4
Covid-19 Vaccine Effectiveness in New York State.纽约州的新冠疫苗有效性。
N Engl J Med. 2022 Jan 13;386(2):116-127. doi: 10.1056/NEJMoa2116063. Epub 2021 Dec 1.
5
Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities - United States, July 2020.11 家门诊医疗机构中≥18 岁有症状成年人中 COVID-19 相关的社区和密切接触者暴露情况-美国，2020 年 7 月。
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1258-1264. doi: 10.15585/mmwr.mm6936a5.
6
"Crude Vaccine Effectiveness" Is a Misleading Term in Test-negative Studies of Influenza Vaccine Effectiveness.“粗疫苗效力”在流感疫苗效力的阴性对照研究中是一个具有误导性的术语。
Epidemiology. 2015 Sep;26(5):e60. doi: 10.1097/EDE.0000000000000343.
Zotero 插件